H.C. Wainwright cuts ProQR stock price target on execution risks

H.C. Wainwright has reduced its price target on ProQR Therapeutics N.V. (PRQR) stock to $8.00 from $12.00, retaining a Buy rating. Analyst Andrew Fein cited execution risks and regulatory uncertainties as the reasons for the reduction. The company's stock is currently trading at $1.66, down 18% year-to-date and 23% over the past year.

Despite this, InvestingPro analysis suggests that ProQR is currently undervalued. The company has more cash than debt and maintains liquid assets exceeding short-term obligations, but it is also rapidly using up its cash reserves—an important factor for investors in pre-revenue biotech firms. ProQR is set to host a research and development day focusing on NTCP modulation in biliary atresia, led by Prof. Gideon Hirschfield.

The company's AX-0810 drug showed clean safety with no serious adverse events, no pruritus, and no bilirubin change, while demonstrating dose-dependent engagement across three biomarkers and an eight-week half-life. H.C. Wainwright believes that advancing AX-0810 and AX-0811 into biliary atresia will validate ProQR's platform clinically, supported by human genetic data and the bilirubin hypothesis in biliary atresia.

ProQR has also received a Buy rating from BofA Securities with a $8.00 price target, emphasizing the significance of AX-0810, the first human validation of ProQR's Axiomer technology.